Recently the use of etidronate in a cyclical fashion has been shown to be of value in the treatment of osteoporosis. Like all bisphosphonates etidronate is structurally similar to pyrophosphate, further it is also known to interfere with phosphate handling by the kidney resulting in elevated plasma phosphate levels. This report describes the case of a patient with established osteoporosis who developed pseudogout associated with cyclical etidronate use. The possible mechanism responsible for this is discussed.
FleischH. Chemistry and mechanisms of action of biphosphates. In: GarattiniS ed. Bon resorption, metastasis and diphosphonates. New York. Raven Press, 1985; p 33–4.
2.
JungA.BisazS.FleischH. The binding of pyrophosphate and two diphosphonates on hydroxyapatite cryustals. Calcif Tissue Res1973; 11: 269–80.
3.
FleischHRussellRGGFrancisMD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science1969; 165: 1262–4.
4.
RalstonSHGardnerMDDryburghFJJenkinsASCowanRABoyleIT. Comparison of aminohydroxypropylidene diphosphonate, mithramycin and corticosteroids/calcitonin in the treatment of cancer-associated hypercalcaemia. Lancet1985; 2: 907–10.
5.
SmithRRussellRGGBishopMCWoodsCGBishopM. Paget's disease of bone: Experience with a diphosphonate (disodium etidronate) in treatment. Quart J Med1973; 42: 235–54.
6.
ReidIRKingARAlexanderCJIbbertsonHK. Prevention of steroid induced osteoporosis with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (APD). Lancet1988; 1: 143–6.
7.
LicataAJacksonRWattsNHarrisDGenantHWasnichRChestnutCMillerP. The effects of cyclical etidronate with or without phosphate in the treatment of postmenopausal osteoporosis: Results of a multicentre study. J Bone Min Res1989; 4, Supp 1: S378.
8.
WaltonRJRussellRGGSmithR. Changes in renal and extra-renal handling of phosphate by disodium etidronate (EHDP) in man. Clin Sci Mol Med1975; 49: 45–56.
